Moderna and Merck's cancer vaccine trial shows 42% reduction in melanoma recurrence

Statements (9)

1. ▲ Bullish

   Moderna presents promising data for its new cancer vaccine

   wiwo.deOct 23, 2026 10:54 UTC
2. ● Neutral

   Moderna and Merck's cancer vaccine lowers melanoma mortality risk by 42 percent according to a study

   wiwo.deOct 23, 2026 05:53 UTC
3. ● Neutral

   Moderna and Merck developed a personalized cancer vaccine that lowers melanoma recurrence by 42%.

   time.comOct 22, 2026 23:54 UTC
4. ● Neutral

   Merck and Moderna reported results on an experimental cancer vaccine that cuts the risk of melanoma recurrence

   nytimes.comOct 22, 2026 22:48 UTC
5. ▲ Bullish

   Moderna and Merck reported that their mRNA cancer vaccine reduced death and recurrence by 42%.

   arstechnica.comOct 22, 2026 22:12 UTCHigh importance
6. ● Neutral

   Moderna and Merck released results of a major trial for a first-of-its-kind cancer vaccine.

   yahoo.comOct 22, 2026 21:39 UTCHigh importance
7. ● Neutral

   Moderna and Merck announced a significant result for their mRNA-based cancer vaccine developed in collaboration.

   portfolio.huOct 22, 2026 18:50 UTCHigh importance
8. ● Neutral

   Moderna is releasing trial results for its cancer vaccine.

   marketwatch.comOct 21, 2026 15:00 UTCHigh importance
9. ▲ Bullish

   Phase 3 cancer vaccine trial for Moderna is successful

   finance.yahoo.comOct 17, 2026 04:21 UTCHigh importance